ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2876

Interleukin-10 Receptor Blockade during Lcmv Infection Results in Macrophage Activation Syndrome-like Disease in Mice

Lehn K. Weaver1 and Edward M. Behrens2, 1Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, 2Pediatric Rheumatology, Childrens Hospital of Philadelphia, Philadelphia, PA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Inflammation, inflammatory cytokines, interleukins (IL), macrophage activation syndrome and viruses

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis II

Session Type: Abstract Submissions (ACR)

Background/Purpose: Macrophage activation syndrome (MAS) is the rheumatic disease-associated member of a group of hyperinflammatory syndromes characterized by uncontrolled cytokine storm manifest as unremitting fevers, cytopenias, splenomegaly, hepatitis, coagulopathy, multisystem organ failure, and death in its most severe form. The clinical features of MAS are shared with other hyperinflammatory syndromes, of which genetic defects in cytotoxicity have provided insight into the pathogenesis driving viral-triggers of disease. However, severe defects in cellular cytotoxicity have not been found in patients with MAS making it unclear how viral infection can trigger hyperinflammation in this condition.

Methods: C57Bl/6, interferon (IFN)γ-/-, and IFNα-/-mice were infected with LCMV Armstrong and treated with or without interleukin (IL)-10 receptor blockade. Survivial, weight loss, splenomegaly, cytopenias, and serum cytokine levels were measured after viral infection.

Results: Wildtype mice treated with IL-10 receptor blockade succumbed to MAS-like hyperinflammation manifest as weight loss, splenomegaly, bicytopenias, and hypercytokinemia during LCMV infection. IFNγ-/- and IFNα-/-mice were not protected from LCMV-induced disease in this model, as they developed severe weight loss, splenomegaly, cytopenias, hypercytokinemia, and more severe mortality when IL-10 receptor was blocked. 

Conclusion: IL-10 receptor blockade leads to heightened immunopathology in the setting of LCMV infection similar to MAS-like hyperinflammatory disease. Unlike other hyperinflammatory syndromes, this immunopathology is independent of IFNγ and IFNα, and highlights the capacity of other inflammatory mediators to cause viral-induced hyperinflammation during IL-10 receptor blockade. Furthermore, these data highlight a novel mechanism that could contribute to MAS-like disease whereby defects in IL-10 production and/or sensing could exacerbate hyperinflammatory immunopathology induced by viral infection without genetic defects in cellular cytotoxicity.


Disclosure:

L. K. Weaver,
None;

E. M. Behrens,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/interleukin-10-receptor-blockade-during-lcmv-infection-results-in-macrophage-activation-syndrome-like-disease-in-mice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology